The in vitro antitumor activity of vitamins C and K3 against ovarian carcinoma

Anticancer Research

Volumn 23, Issue 4, 2003, Pages 3279-3287

  Von Gruenigen, Vivian E ^a,b,d   Jamison, James M ^a,b   Gilloteaux, Jacques ^a   Lorimer, Heather E ^c   Summers, Marcia ^a,b   Pollard, Robert R ^a,b   Gwin, Carley A ^a,b   Summers, Jack L ^a,b  

^a SUMMA HEALTH SYSTEM   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c YOUNGSTOWN STATE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Autoschizis; Ovarian cancer; Vitamin C; Vitamin K3

Indexed keywords

ASCORBIC ACID; CELL DNA; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MENADIONE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CHROMOSOME; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DNA DEGRADATION; DNA ISOLATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; EVALUATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT; OVARY CARCINOMA; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCORBIC ACID; CELL DIVISION; DNA, NEOPLASM; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; MICROSCOPY, ELECTRON; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; VITAMIN K 3;

EID: 0041528197     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Eisenberg DM, Davis RB and Ettner SL: Trends in alternative medicine use in the United'States, 1990-1997. JAMA 280(18): 1569-1575, 1998.
2. von Gruenigen VE, White L, Hopkins MP, Mazi M and Jenison EJ: The comparison of complementary and alternative medicine between gynecologic and gynecologic oncology patients. Int J Gynecol Cancer 11(3): 205-9, 2001.
3. Heber D, Blackburn GL and Go VLW: Nutritional Oncology, San Diego, CA, Academic Press, 1999.
4. Saintot M, Astre C, Pujol H and Gerber M: Tumor progression and oxidant-antioxidant status. Carcinogenesis 17(6): 1267-1271, 1996.
5. Suzuki T, Ezure T and Ishida M: Synergistic effects of some pairs of antioxidants and related agents on mouse leukaemia L5178Y cell growth in vitro. J Pharm Pharmacol 50: 173-1177, 1998.
6. De Laurenzi V, Melino G, Savini I, Annicchiarico-Petruelli M, Finazzi-Agro A and Avigliano L: Cell death by oxidative stress and ascorbic acid regeneration in human neuroectodermal cell lines. Eur J Cancer 31: 463-466, 1995.
7. Tsao CS: Inhibiting effect of ascorbic acid on the growth of human mammary tumor xenografts. Am J Clin Nutri 54(6): 124-1280, 1991.
8. Sakagami H, Satoh K, Hakeda Y and Kumegawa M: Apoptosis-inducing activity of vitamin C and vitamin K. Cell Mol Biol 46(1): 129-143, 2000.
9. Wu FY, Liao WC and Chang HM: Comparison of antitumor activity of vitams K1, K2, and K3 of human tumor cells by two (MTT and SRB) cell viability assays. Life Sci 52(22): 1797-804, 1993.
10. Nutter LM, Cheng AL, Hung HL, Hsieh RK, Ngo EO and Liu TW: Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. Biochem Pharmacol 41(9): 1283-92, 1991.
11. Okayasu H, Ishihara M, Satoh K and Sakagami H: Cytotoxic activity of vitamins K1, K2 and K3 against human oral tumor cell lines. Anticancer Res 21: 2387-2392, 2001.
12. 3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action. Cancer 63(5): 901-6, 1989.
13. 3 on human urologic tumor cell lines. Life Sci 59: 1389-1400, 1996.
14. 3 against human prostate carcinoma cell lines. Cell Biol Intl 20: 787-797, 1996.
15. 3 combinations against human prostatic carcinoma cells. Scanning Microsc 9: 159-173, 1995.
16. 3 combinations against human prostatic carcinoma cells. Tissue Cell 28: 687-701, 1996.
17. 3 combinations against human prostate cancer. J Nutr 131(1): 158S-160S, 2001.
18. Gilloteaux J, Jamison JM, Arnold D, Taper HS and Summers JL: Ultrastructural aspects of autoschizis: a new cancer cell death induced by the synergistic action of ascorbate/menadione on human bladder carcinoma cells. Ultrastruct Pathol 25(3): 183-192, 2001.
19. 3 combination. J Histochem Cytochem 49: 109-119, 2001.
20. Freedman R, Pihl E, Kusyk C, Gallager HS and Rutledge F: Characterization of an ovarian carcinoma cell line. Cancer 42: 2352-2359, 1978.
21. Buick RN, Pullano R and Trent JM: Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 45(8): 3668-3676, 1985.
22. Lau DH, Lewis AD, Ehsan MN and Sikic BI: Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 51(19): 5181-5187, 1991.
23. von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS and Mathis JM: In vivo studies adenovirus-based p53 gene therapy for ovarian cancer. Gynecol Oncol 69(3): 197-204, 1998.
24. Vindelov LL, Christensen IJ and Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometry DNA analysis. Cytometry 3: 323-327, 1983.
25. 3 on human bladder carcinoma T24 cells. Scanning 20: 564-575, 1998.
26. Sambrook J, Fritsch EF and Maniatis T: (1982) Molecular Cloning. A Laboratory Manual, 2nd Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
27. Gilloteaux J, Jamison JM, Ervin E, Arnold D and Summers JL: Scanning electron microscopy and transmission electron microscopy aspects of the synergistic antitumor activity of vitamin C/ vitamin Ks combinations against human T24 bladder carcinoma: another kind of death? Scanning 20(3): 208-209, 1998.
28. Thomas MJ: The role of free radicals and antioxidants. Nutrition 16(7/8): 716-718, 2000.
29. Levine M, Rumsey SC, Daruwala R, Park JB and Wang Y: Criteria and recommendations for vitamin C intake. JAMA 281: 1415-1423, 1999.
30. Jarabak R, Harvey RG and Jarabak J: Redox cycling of polycyclic aromatic hydrocarbon o-quinones: superoxide dismutase inhibition by ascorbate. Arch Biochem Biophys 339(1): 92-8, 1997.
31. Gerber M, Astre C, Segala C, Saintot M, Scali J, Simony-lafontaine J et al: Oxidant-antioxidant status alterations in cancer patients: relationship to tumor projression. J Nutr 126: 1201-1207, 1996.
32. Kurbacher C, Wagner U, Kolster B et al: Ascorbic acid (vitaminC) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103: 183-189, 1996.
33. Lamson DW and Brignall MA: Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev 4(5): 304-329, 1999.
34. Reilly P, Gignac M, Chue B and Sardo M: Concerns over antioxidant-chemotherapy interactions overstated. Oncology 13(12): 1627-1628, 1999.
35. Prasad KN, Cole WC, Kumar B and Prasad KC: Scientific rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental cancer therapies. J Am Coll Nutr 20(5Suppl): 450S-463S, 2001.
36. Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ et al: Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomized trial. Ann Oncol 8(6): 569-73, 1997.
37. Hoffer A and Pauling L: Hardin Jones biostatistical analysis of mortality data for a second set of cohorts of cancer patients with a large fraction surviving at the termination of the study and a comparison of survival times of cancer patients receiving large regular oral does of Vitamin c and other nutrients with similar patients not receiving these doses. J Orthomolecular Medicine 8(3): 157-167, 1993.
38. Lockwood K, Moesgaard S, Hanioka T and Folkers K: Apparent partial remission of breast cancer in high risk patients supplemented with nutritional antiooxidants, essential fatty acids and coenzyme q10. Molec Aspects Med 15: 231-240, 1994.
39. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ and Ames MM: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chmotherapy. A randomized double-blind comparison. N Engl J Med 312(3): 137-41, 1985.
40. Tetef M, Margolin K, Ahn C, Akman S, Chow W, Coluzzi P et al: Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial. J Cancer Res Clin Oncol 121: 103-106, 1995.
41. 3 vitamin pre-treatment. Int J Cancer 40: 575-579, 1987.
42. 3 pretreatment in a mouse tumor resistant to oncovin. Anticancer Res 12: 1651-1654, 1992.
43. 3 in mice bearing solid transplantable tumor. Anticancer Res 16: 499-504, 1996.
44. Tetef M, Margolin K, Ahn, Akman S, Chow W, Leong L et al: Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Investigational New Drugs 13: 157-162, 1995.
45. Fort L, Taper H and Brucher JM: Nuclease activity in different segments of the human digestive tube compared to the incidence of carcinomas Histochemistry 20: 150-158, 1969.
46. Taper HS, Deckers C and Deckers-Passau LO: Increase in nuclease activity as a possible means for detecting tumor cell sensitivity to anticancer agents. Cancer 47: 523-527, 1981.
47. 3. Anticancer Res 21(5): 3439-3444, 2001.
48. Hetts SW: To die or not to die. JAMA 279(4): 300-307, 1998.
49. 3-induced death of human bladder tumor cells. Scanning 20: 210-211, 1999.
50. Gilloteaux J, Jamison JM, Arnold D and Summers JL: Autoschizis: another cell death for cancer cells induced by oxidative stress. Ital J Anat Embryol 106: 79-92, 2001.
51. Jamison JM, Gilloteaux J, Taper HS, Calderon PB and Summers JL: Autoschizis: a novel cell death. Biochem Pharmacol 63(10): 1773-1783, 2002.